Corrigendum to "Resolving HER2 status in breast carcinoma patients with complete deletion of CEP17 in fluorescence in-situ hybridization assays" [Cancer Genetics, 296-297, 2025, 196-199].

Cancer Genet

The Institute for Experimental Pathology®, ARUP Laboratories, Salt Lake City, UT, USA; Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT, USA. Electronic address:

Published: September 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergen.2025.08.002DOI Listing

Publication Analysis

Top Keywords

corrigendum "resolving
4
"resolving her2
4
her2 status
4
status breast
4
breast carcinoma
4
carcinoma patients
4
patients complete
4
complete deletion
4
deletion cep17
4
cep17 fluorescence
4

Similar Publications

In this study, we evaluated the quantitative capabilities of a GC-APCI trapped ion mobility (TIMS) TOF platform for the determination of ultra-trace levels of polychlorinated dibenzo-p-dioxins (PCDD/Fs) and polychlorinated biphenyls (PCBs) in complex food matrices. Using a Bruker timsTOF Pro 2 instrument, three fat-based proficiency test samples - fish oil, palm oil, and milk fat - were analyzed and compared to a validated GC-sectorHRMS method, in accordance with the criteria set by Commission Regulation (EU) 2017/644. Linearity was confirmed across broad dynamic ranges, with relative response factor (RRF) precision consistently below 20 %.

View Article and Find Full Text PDF

The time-resolved atomic, molecular and optical science instrument at the Linac Coherent Light Source. Corrigendum.

J Synchrotron Radiat

July 2025

SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, CA 94025, USA.

The name of an author in the article by Walter et al. (2022) [J. Synchrotron Rad.

View Article and Find Full Text PDF